Literature DB >> 8313384

Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI.

E C Kohn1, C C Felder, W Jacobs, K A Holmes, A Day, R Freer, L A Liotta.   

Abstract

Evidence is accumulating that calcium homeostasis and calcium-regulated events may be selectively important in generation and maintenance of the malignant phenotype. CAI, a carboxyamido-triazole with a halogenated benzophenone tail, is a novel inhibitor of receptor-operated calcium influx and arachidonic acid release which inhibits malignant proliferation, invasion, and metastasis. The focus of this investigation was structural analysis of CAI and to determine if the inhibition of calcium influx and arachidonic acid release by CAI and its antiproliferative activity were mediated through the same chemical domains. Four families of molecular modifications of the CAI parent were synthesized: (I) modification or substitution of the triazole ring; (II) removal of the substituted benzophenone tail; (III) dehalogenation or partial truncation of the benzophenone moiety; and (IV) removal of the triazole and altered substitutions of the benzophenone tail. Compounds were tested for the inhibition of calcium influx and arachidonic acid release and inhibition of proliferation and colony formation in soft agar using the malignant CHO line transfected with the m5 muscarinic receptor and the A2058 human melanoma cell line. Only CAI and Group I compounds inhibited stimulated calcium influx, arachidonic acid release, and proliferation. Linear regression analysis of the relationship of the 50% inhibitory concentration values for all compounds in inhibition of calcium influx and arachidonate release was statistically significant (r2 = 0.993). Similarly, a linear relationship was demonstrated between inhibition of calcium influx and inhibition of tumor cell proliferation (r2 = 0.971). Groups II-IV had minimal or no signal or growth inhibitory activity. This investigation provides the first evidence for a coordinate link between calcium influx, calcium-mediated arachidonic acid release, and malignant proliferation and metastasis and constitutes the initial analysis of structurally important domains of the CAI molecule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8313384

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Cloning and expression of the functional human anti-vascular endothelial growth factor (VEGF) using the pcDNA3.1 vector and the human chronic myelogenous leukemia cell line K562.

Authors:  Masoumeh Hajirezaei; Mojtaba Darbouy; Bahram Kazemi
Journal:  Protein J       Date:  2014-02       Impact factor: 2.371

2.  Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Authors:  Antonio Omuro; Kathryn Beal; Katharine McNeill; Robert J Young; Alissa Thomas; Xuling Lin; Robert Terziev; Thomas J Kaley; Lisa M DeAngelis; Mariza Daras; Igor T Gavrilovic; Ingo Mellinghoff; Eli L Diamond; Andrew McKeown; Malbora Manne; Andrew Caterfino; Krishna Patel; Linda Bavisotto; Greg Gorman; Michael Lamson; Philip Gutin; Viviane Tabar; Debyani Chakravarty; Timothy A Chan; Cameron W Brennan; Elizabeth Garrett-Mayer; Rashida A Karmali; Elena Pentsova
Journal:  J Clin Oncol       Date:  2018-04-23       Impact factor: 44.544

3.  Mechanisms of integrin-mediated calcium signaling in MDCK cells: regulation of adhesion by IP3- and store-independent calcium influx.

Authors:  M D Sjaastad; R S Lewis; W J Nelson
Journal:  Mol Biol Cell       Date:  1996-07       Impact factor: 4.138

4.  Activation of NALP1 inflammasomes in rats with adjuvant arthritis; a novel therapeutic target of carboxyamidotriazole in a model of rheumatoid arthritis.

Authors:  Lei Zhu; Juan Li; Lei Guo; Xiaoli Yu; Danwei Wu; Lifeng Luo; Lingzhi Zhu; Wei Chen; Chen Chen; Caiying Ye; Dechang Zhang
Journal:  Br J Pharmacol       Date:  2015-05-05       Impact factor: 8.739

5.  Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-κB and activating SIRT1.

Authors:  Chen Chen; Rui Ju; Lei Zhu; Juan Li; Wei Chen; De-Chang Zhang; Cai-Ying Ye; Lei Guo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-25       Impact factor: 3.000

6.  Inhibitory effects of CAI in glioblastoma growth and invasion.

Authors:  W Jacobs; T Mikkelsen; R Smith; K Nelson; M L Rosenblum; E C Kohn
Journal:  J Neurooncol       Date:  1997-04       Impact factor: 4.130

7.  A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.

Authors:  Stephan Hoffmann; Shikun He; Manlin Jin; Marianne Ehren; Peter Wiedemann; Stephen J Ryan; David R Hinton
Journal:  BMC Ophthalmol       Date:  2005-06-29       Impact factor: 2.209

8.  A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.

Authors:  Nilofer Azad; Alyssa Perroy; Erin Gardner; Chiyo K Imamura; Cynthia Graves; Gisele A Sarosy; Lori Minasian; Herbert Kotz; Miranda Raggio; William D Figg; Elise C Kohn
Journal:  Cancer Biol Ther       Date:  2009-10       Impact factor: 4.742

9.  Angiogenesis: role of calcium-mediated signal transduction.

Authors:  E C Kohn; R Alessandro; J Spoonster; R P Wersto; L A Liotta
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 10.  Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation.

Authors:  Larissa Lipskaia; Jean-Sébastien Hulot; Anne-Marie Lompré
Journal:  Pflugers Arch       Date:  2008-01-11       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.